ArticleOncology letters2026
Clinicopathological characteristics and potential impact of previous treatment history in metachronous contralateral breast cancer: Insights from a real-world retrospective study.
Article in Oncology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metachronous contralateral breast cancer (mCBC) accounts for 40-50% of new secondary cancers in breast cancer survivors. With improved breast cancer treatment outcomes, the number of long-term survivors is increasing. To better understand the clinical features of mCBC in real-world practice, patients who developed mCBC, defined as contralateral second primary breast cancer diagnosed ≥12 months after the first primary breast cancer (FBC), were retrospectively analyzed. Two types of comparisons were conducted: i) A within-patient comparison between FBC and mCBC (n=115) to evaluate paired differences in tumor characteristics; and ii) a between-patient comparison of the mCBC cohort with a unilateral breast cancer (UBC; n=1,877) cohort of patients who remained recurrence-free for ≥5-10 years to assess differences in baseline clinical features and indicators related to hereditary cancer risk, thereby identifying features unique to mCBC. The median age at diagnosis was 48 years for FBC in patients who subsequently developed mCBC and 55 years for UBC, with a significant difference (P<0.001). The median time interval from FBC to mCBC onset was 9 (1-44) years. The stage at diagnosis was significantly earlier in mCBC than in FBC (P<0.001). Among patients with mCBC, prior chemotherapy (CTx) for FBC was associated with lower odds of the luminal subtype relative to the triple-negative subtype compared with no prior CTx, although this association was not statistically significant (P=0.086). The proportion of patients with a first-degree family history was significantly higher in patients with mCBC than in patients with UBC (P=0.025). No significant association was observed between family history and the timing of mCBC onset. Further adequately powered studies are warranted to clarify whether prior CTx influences the molecular subtype of mCBC (P=0.602). The present results highlighted the importance of family history assessment and the need for lifelong surveillance in breast cancer survivors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.